OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

Podcast

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.

As part of its OncView™ video series, CancerNetwork® spoke with John Kirkwood, MD, PhD, director of the Melanoma Center at the University of Pittsburgh Medical Center Hillman Cancer Center, about using immunotherapy for treating melanoma and how to properly monitor responses in patients with metastatic melanoma.

In the video series, Kirkwood discussed the following:

To watch more videos from the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Related Videos
Experts on myeloma
Related Content
Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.

Selecting Observation Vs Immunotherapy in Advanced Melanoma

April 2nd 2024
Article

Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.

On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

February 14th 2022
Podcast

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.

The DermaSensor device demonstrates a high rate of sensitivity in the detection of more than 200 types of skin cancers in a clinical study.

FDA Clears Non-Invasive AI Device for Skin Cancer Detection

January 18th 2024
Article

The DermaSensor device demonstrates a high rate of sensitivity in the detection of more than 200 types of skin cancers in a clinical study.

Dissecting Adjuvant Therapy Options in Melanoma

Dissecting Adjuvant Therapy Options in Melanoma

January 4th 2019
Podcast

Cancer Network speaks with Dr. Ryan J. Sullivan about adjuvant therapies in development for melanoma patients.

Individualized Neoantigen Therapy/Pembrolizumab Improves RFS in Melanoma

Individualized Neoantigen Therapy/Pembrolizumab Improves RFS in Melanoma

December 18th 2023
Article

mRNA-4157 is being evaluated in combination with pembrolizumab as part of the phase 2b KEYNOTE-942/mRNA-4157-P201 trial in patients with completely resected, high-risk, stage III to IV melanoma.

Treatment with mRNA-4157 plus pembrolizumab yields benefits in resected melanoma subgroups in the phase 2 KEYNOTE-942 trial, including those with BRAF-mutated tumors.

mRNA Vaccine/Pembrolizumab Significantly Improves RFS in Resected Melanoma

October 23rd 2023
Article

Treatment with mRNA-4157 plus pembrolizumab yields benefits in resected melanoma subgroups in the phase 2 KEYNOTE-942 trial, including those with BRAF-mutated tumors.